Global Vision

The Good, The Bad, And The Uncertain: Trump’s Second Administration And The Rx Industry

 
• By 

The pharma industry arguably suffered none of the downside risks that were possible during the first Trump administration, and their relationship with Biden could not have gone much worse. And while they may hope a Trump return could help their fortunes, having RFK Jr. supervising the FDA is likely not the prescription they want.

Big Pharma GCCs In India: From Back-Office Ops To Innovation Catalysts

 

India is seeing a flurry of activity with big pharma either establishing or expanding their global capability centers in the country. Can these hubs reshape the contours of industry’s operating model across a range of functions and perhaps spawn a pipeline of new leaders along the way?

The BIOSECURE Act: What Does It Mean For The Off-Patent Industry?

 

As China faces the potential loss of a big customer base, the US off-patent industry starts to look for new relationships elsewhere. While building domestic manufacturing capabilities would be the ultimate American dream, the government has yet to offer the carrot, not just the stick.

China Makes Its Presence Felt In Asia 100 Sales

 
• By 

While Japanese firms still dominate the money spinners in Asia, companies from China and, lesser so, India are starting to stand out from the crowd.


Bristol Myers Squibb ASPIREs For Access In LMICs

 

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

Humira Pricing Takes Center Stage In Dutch Courts

 
• By 

A public interest group has accused the pharma major of using excessive pricing to bolster sales of blockbuster Humira, consequently damaging the health of Dutch patients. 

Taiwanese Startup Awarded Top Prize At 2024 MedTech Innovator Asia Pacific Accelerator

 
• By 

APrevent, a laryngeal implant developer from Taiwan, was named the overall winner of the annual MedTech Innovator APAC accelerator award for 2024. Awards managing director Fredrik Nyberg talked to In Vivo about the rising importance of the APAC region’s hub of companies providing innovative medtech.

Teva CEO Francis Urges UK To ‘Wake Up And Understand’ Life Sciences Potential

 
• By 

The potential of the UK’s life sciences sector continues to be critically misunderstood and should be the cornerstone of both society and the economy, according to Teva’s CEO Richard Francis.  


Spain Consults On HTA Regulations

 

New rules on health technology assessments in Spain make room for real-world evidence and early dialog.  

Kiji Takes Flight With Off-The-Shelf Stem Cells

 
• By 

Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to prove cell therapy manufacturing doesn’t need to decelerate commercial viability.  

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Why Is Animal Testing Still With Us?

 
• By 

Despite increased openness by regulators and technological progress, the adoption of alternatives to animal testing remains challenging. The need for data validation by agencies and companies is a big factor.


H2 Investment Life Sciences Uptick Anticipated But Markets Remain Enduringly Cautious

 
• By 

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

WIAT Global: Addressing Inequalities And Following The CAR-T Journey After Treatment

 

The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.

Tackling The Challenge Of Malaria Clinical Trials In Africa

 
• By 

Novartis leads the fight against malaria, pioneering innovative studies in sub-Saharan Africa to combat parasite resistance to current antimalarials.

After Humira Biosimilars, Will It Be Groundhog Day For Stelara?

 
• By 

With ustekinumab biosimilars set to launch in Europe imminently and in the US early next year, the off-patent industry may be wondering whether it will be in for a rerun of its experiences with competition on Humira – or whether the landscape has changed sufficiently to allow for different pricing and uptake trends. 


Podcast: Improving Communication – The Relationship Between Biotech And Pharma

 
• By 

Ali Pashazadeh, CEO, chair and founder of Treehill Partners discusses the need for increased communication between biotech and biopharma. 

China Market For Medtech: Opportunity Or Headache?

 
• By 

Medtech companies have typically seen a “mixed picture of growth” in China in the past year or two, but it is a market that requires ongoing commitment, a panel of experts argued at the MedTech Forum 2024.

Poland’s Quiet Pivot From Generics To Innovative Treatments

 
• By 

Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.  

China’s CAR T-Cell Therapy Industry Booms With Shanghai At Center

 
• By 

According to China Pharmaceutical Innovation and Research Development Association, in the first quarter of 2024 a total of 44 cell therapies in the domestic cell therapy field made clinical application progress, including 28 immune cell therapies and 16 stem cell therapies.